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Abstract
Induced pluripotent stem cell (iPSC) technology has enormous potential to provide improved 
cellular models of human disease. However, variable genetic and phenotypic characterisation of 
many existing iPSC lines limits their potential use for research and therapy. Here, we describe the 
systematic generation, genotyping and phenotyping of 711 iPSC lines derived from 301 healthy 
individuals by the Human Induced Pluripotent Stem Cells Initiative (HipSci: http://
www.hipsci.org). Our study outlines the major sources of genetic and phenotypic variation in 
iPSCs and establishes their suitability as models of complex human traits and cancer. Through 
genome-wide profiling we find that 5-46% of the variation in different iPSC phenotypes, including 
differentiation capacity and cellular morphology, arises from differences between individuals. 
Additionally, we assess the phenotypic consequences of rare, genomic copy number mutations that 
are repeatedly observed in iPSC reprogramming and present a comprehensive map of common 
regulatory variants affecting the transcriptome of human pluripotent cells.
Introduction
Induced pluripotent stem cells (iPSCs) are important model systems for human disease1. A 
major open question is whether iPSCs can be used to study the functions of genetic variants 
associated with complex traits and normal human phenotypic variation. Previous work has 
suggested that individual iPSC lines are highly heterogeneous2–5, although some of these 
differences may arise due to genetic background of the donor6,7. Nonetheless, high 
variability could make iPSCs unsuitable cellular models for genetic variants with small 
effects. Existing iPSC lines also frequently have limited genetic and phenotypic data of 
variable quality, or are derived from individuals with severe genetic disorders, limiting their 
utility for studying other phenotypes.
The Human Induced Pluripotent Stem Cells Initiative (HipSci: www.hipsci.org) was 
established to generate a large, high-quality, open-access reference panel of human iPSC 
lines. A major focus of the initiative is the systematic derivation of iPSCs from hundreds of 
healthy volunteers using a standardised and well-defined experimental pipeline. The lines 
are extensively characterised and available to the wider research community along with the 
accompanying genetic and phenotypic data. Here, we report initial results from the 
characterization of the first 711 iPSC lines derived from 301 healthy individuals. We provide 
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a high-resolution map of recurrent copy number aberrations in iPSCs, identify putative 
candidate genes under selection in these regions, and assess the functional consequences of 
these changes. We show that common genetic variants produce readily detectable effects in 
iPSCs and provide the most comprehensive map of regulatory variation in human iPSCs to 
date. We also demonstrate that differences between donor individuals have pervasive effects 
at all phenotypic levels in iPSCs, from the epigenome, transcriptome and proteome to cell 
differentiation and morphology.
Sample collection and iPSC derivation
Samples were collected from healthy, unrelated research volunteers via the NIHR 
Cambridge BioResource (Methods). We established 711 lines from 301 donors (>1 line for 
82% of donors, >2 lines for 50%), which were profiled using an initial set of ‘Tier 1‘ assays 
(Fig. 1a). These included array-based genotyping and gene expression profiling of the iPSCs 
and their fibroblast progenitors, as well as an assessment of the pluripotency and 
differentiation properties of the iPSCs. Using immunohistochemistry followed by 
quantitative image analysis (hereafter ‘Cellomics’), we measured protein expression of 
pluripotency markers in 307 lines and differentiated 372 lines into neuroectoderm, 
mesoderm, and endoderm8 measuring expression of three lineage-specific markers in each 
germ layer (Fig. 1a; Extended Data Fig. 1). We then selected 1-2 lines per donor to minimise 
the number of genetic abnormalities and performed further phenotyping (hereafter ‘Tier 2’) 
using RNA-seq, DNA methylation arrays, quantitative proteomics and cell morphological 
imaging in 239, 27, 16 and 24 lines, respectively (Supplementary Table 1).
Pluripotency and genetic stability
Using Tier 1 expression data, 84% of our lines were classified as pluripotent by PluriTest9 
(score > 20) and 97% had a pluripotency score of >10, which yields almost identical 
sensitivity and specificity in the PluriTest training set (Fig. 1b). Most lines with a 
pluripotency score <20 (69%) had been cultured on feeder free Essential 8 media (OR 5.4, P 
< 8x10-13, Fisher’s exact test), which likely reflects that PluriTest was primarily trained 
using lines grown in feeder-dependent conditions (Extended Data Fig. 2). Using the 
Cellomics imaging data we quantified the fraction of cells expressing each pluripotency 
marker individually and estimated that, on average, between 18% and 62% of cells in the 
iPSC lines co-expressed all three markers NANOG, POU5F1 (OCT4) and SOX2 (Fig. 1c). 
Almost all lines (>99%) successfully produced cells from all three germ layers during 
directed differentiation with the average line producing up to 70%, 84% and 77% of cells 
expressing all three markers of dEN, dME and dEC, respectively (Fig. 1d). We assessed 
correlations of differentiation capacity between different germ layers and found a positive 
correlation between endoderm and mesoderm marker expression (Spearman r = 0.36, P < 
0.001), and between endoderm and pluripotency marker expression (Spearman r = 0.21, P < 
0.008) (Extended Data Fig. 1c). Taken together, our data indicate that virtually all of the 
iPSC lines we have derived are pluripotent, although we observed some variability in 
differentiation between lines.
Next, we used genotyping arrays to detect copy number alterations (CNAs) between the 
iPSC lines and their progenitor fibroblasts. For this purpose, we developed a computational 
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approach10 that can detect genetic abnormalities of >200 Kb occurring in 20% or more 
cells. We identified trisomies in 4% of lines (none of the selected lines), and 41% of lines 
(18% of the selected lines) harboured one or more CNAs of, on average, 7.15 Mb in length 
with duplications outnumbering deletions by 2.8 to 1 (Fig. 1e, Supplementary Table 2). 
Although the majority of CNAs were unique to single iPSC lines, 22% were also observed 
in at least one replicate line from the same donor (at least one base pair overlap), and 15% 
were identified in all replicates (Fig. 1f). We found no significant association between the 
number of CNAs and either passage number, donor age, gender or PluriTest score of a line 
(P > 0.09, Fig. 1g, Extended Data Fig. 3).
CNAs observed in pluripotent stem cells (PSCs) are known to recur at certain genomic 
locations11–13. We observed 35 regions where CNAs occurred significantly more often than 
expected under a uniform genomic distribution, including whole chromosome duplication of 
the X chromosome (P = 1.5x10-9), 20 sub-chromosomal duplications, 11 deletions and three 
regions with both duplications and deletions (Fig. 2a, Supplementary Table 2). The three 
most frequent CNAs (X trisomy, chromosome 17 and 20) have been previously observed in 
PSCs12,14,15, but others are newly identified, to our knowledge.
Although recurrent CNAs could be due to mutational hotspots we did not find a significant 
overlap between our recurrent CNA set and annotated chromosome fragile sites16 (17% 
overlap, P = 0.075). Recurrent CNAs could also arise if duplication or deletion of specific 
genes led to a selective advantage. To identify potential targets of selection, we defined peak 
regions of amplification (regions of maximum recurrence e.g. Fig. 2c and Extended Data 
Fig. 4) within each CNA and identified expressed genes (FPKM>0 in >10% of lines). 
Fourteen candidate regions contained fewer than six expressed genes including genes with 
establised roles in cancer progression (DOCK1, FATS, WWOX, STAG2 and XIAP)17–21. 
In regions with larger numbers of genes we searched for: (i) significant differential 
expression between lines with copy number 2 and 3 (ii) reported oncogenes from 
COSMIC20 and (iii) high scoring genes (top 2%) in a genome-wide siRNA screen for hESC 
cell proliferation22 (Fig. 2c, Extended Data Fig. 4; Supplementary Table 2). This approach 
identified BCL2L112 on chr20q11.21, EIF4A3, NOL11 and seven other genes on chr17q 
and UTP6 and SUZ12 on chr17q11.2. One candidate, EIF4A3, scored more highly than 
BCL2L1 in reducing ESC proliferation (Fig. 2c, top 0.1% of genes), was highly expressed in 
iPSCs, and over-expressed in lines with increased copy number, at both the mRNA (Q = 
2x10-5) and protein level (Extended Data Fig. 5). Finally, we compared lines from the same 
donor with and without CNAs to test for genome-wide effects on gene expression levels and, 
in a subset of cases, for effects on cell growth, proliferation and apoptosis (Fig. 2b, Extended 
Data Fig. 5). The recurrent duplication on chromosome 17 was associated with the largest 
number of changes in gene expression, including 1,098 genes (FDR < 1%) in trans located 
on other chromosomes, which were enriched for ‘Neural Crest Differentiation’ and ‘DNA 
strand elongation’ pathways (PathCards23, Supplementary Table 2). We also detected 
significant increases and decreases in cell growth rate associated with CNAs on chromosome 
17 and 20 (Extended Data Fig. 5).
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Sources of iPSC heterogeneity
Characterisation of multiple lines per donor enabled us to quantify the variance contributed 
by between-individual differences (hereafter, ‘donor effects’) and systematically compare 
this with variance from other factors, substantially extending previous analyses in smaller 
cohorts6,7 (Fig. 3a-c). We identified consistent donor effects for most measured iPSC 
phenotypes, ranging from DNA methylation, through mRNA and protein abundance to 
pluripotency, differentiation, and cell morphology (Fig. 3b,c). After accounting for assay-
specific batch factors (full list in Methods), donor effects explained 5.2-26.3% of the 
variance in the genome-wide assays (Fig. 3a), 21.4-45.8% in protein immunostaining (Fig. 
3b), and 7.8-22.8% in cellular morphology (Fig. 3c). Collectively, these results indicate that 
differences between donor individuals affect most iPSC cellular traits.
We further partitioned iPSC gene expression variation using the Tier 1 expression array data, 
the assay with the largest number of donors and lines. Of the 25,434 probes analysed 
(16,829 genes) (Supplementary Table 3), donor effects explained the largest proportion of 
variation in 46.4% of probes (53.3% of genes), substantially more than any other factor, 
including copy number status (23.4%), culture conditions (26.2%), passage (2%) and gender 
(1.9%, Fig. 3d). Donor effects were common, and consistent across large numbers of genes, 
while others such as CNA status had larger effects on a smaller number of genes (Fig. 3d). 
We observed minor effects of gender and line passage number on RNA-seq, methylation and 
protein immunofluorescence (Fig. 3d, Extended Data Fig. 6). Likewise, we did not observe 
substantial changes in PluriTest scores, or pluripotency marker expression across passages 
(P > 0.3, Extended Data Fig. 6), reflecting that pluripotency was maintained during culture. 
In principle, the estimated donor variation could arise due to shared reprogramming 
environment because lines were derived from the same population of fibroblast cells. 
However, expression quantitative trait locus (eQTL) effect sizes mapped using Tier 1 
expression data (Supplementary Table 4, Extended Data Fig. 6) revealed that higher donor 
variation was associated with larger effect sizes of lead eQTL variants (Fig. 3e), suggesting 
that donor variance primarily reflects genetic differences.
Identification and characterization of iPSC-specific regulatory variants
Using RNA-seq data from 166 unrelated donors (median sequencing depth 38M reads), we 
next mapped eQTLs in a 1 Mb cis-window from the gene start. We identified 6,631 genes 
with an eQTL (FDR 5%, hereafter ‘eGenes’), 598 of which had a significant secondary 
eQTL (Supplementary Table 4). Power to discover eGenes in iPSCs was comparable to that 
in somatic tissues24 given our sample size, and iPSC eQTLs showed similar genomic 
properties to eQTLs in cell lines and tissues (Extended Data Fig. 7; Supplementary Table 5).
As many eQTLs are shared among tissues9,25,26, we sought to place iPSC eQTLs in the 
broader context of somatic tissues. We assessed iPSC eQTL replication across 44 GTEx 
tissues (lead eQTLs and proxy variants, r2 > 0.8, defining replication as P < 0.01/45; 
Methods), revealing 2,131 eQTLs that were specific to iPSCs (Fig. 4a). We also considered 
secondary eQTLs, identifying a similar proportion of iPSC-specific genetic effects (both 
32%). Most tissue-specific signals (72%) occurred in genes with at least one GTEx eQTL 
that was not in high linkage disequilibrium (LD) with the lead iPSC eQTL variant, 
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suggesting that iPSC-specific eQTLs are frequently driven by alternative regulatory variants. 
Only 11% of the iPSC-specific eQTLs could be attributed to tissue-specific gene expression 
(Fig. 4b), despite greater numbers of expressed genes in iPSCs compared with somatic 
tissues (Extended Data Fig. 7). Similarly, most somatic tissue-specific eQTLs were also 
driven by alternative regulatory variants, with only testis showing a substantial fraction 
(16%) of eQTLs attributable to tissue-specific gene expression (Fig. 4b). Using alternative 
methods for eQTL detection and assessing the extent of sharing between eQTLs in iPSCs 
and GTEx tissues, we confirmed that our conclusions were robust to methodological 
differences between GTEx and our study (Extended Data Fig. 8). However, due to variation 
in sample size, we cannot rule out that a fraction of the iPSC-specific eQTLs may have a 
weak effect on gene expression in some somatic tissues.
The transcriptional regulatory networks that maintain pluripotency are unique to stem cells. 
We next investigated how common genetic variants modulate these networks to produce 
iPSC-specific genetic effects on expression. We used chromatin state annotations from 127 
reference epigenomes from the Roadmap Epigenomics Project27 to quantify the fold 
enrichment of iPSC-specific and nonspecific eQTL sets across 25 chromatin states (using 
matched null variants; Methods). iPSC-specific eQTLs were enriched in active enhancers 
and poised promoters in PSCs and PSC-derived cell types, while shared eQTLs were 
enriched for active promoters and transcribed regions in somatic tissues (Fig. 4c). iPSC-
specific eQTLs were also enriched for binding sites of NANOG, POU5F1 (OCT4), and 
multiple other pluripotency factors9,28 (Fig. 4d; Extended Data Fig. 8). Our results suggest 
that common genetic differences between individuals may affect expression regulation 
during early stages of development.
iPSC eQTLs tag common disease variants
We next identified iPSC eQTLs that may be associated with disease. iPSC eQTLs tagged 
322 variants associated in genome-wide association studies with 145 different disease traits, 
corresponding to a 1.4-fold global enrichment over control variants (Fisher’s exact P = 
1.4x10-6), and trait-specific enrichments for seven traits (Supplementary Table 6), a 
comparable level of enrichment to eQTLs from most somatic tissues (Extended Data Fig. 9). 
We also observed that iPSC eQTLs tagged a larger number of known cancer genes 
(COSMIC cancer census 27/04/201620) than somatic tissue eQTLs, with only cancer eQTLs 
tagging more (Extended Data Fig. 9).
Next, we used statistical colocalisation29 to identify loci where the same causal variant 
appeared to be driving both an iPSC eQTL and an association with one of 14 complex traits, 
identifying 233 loci where the posterior probability of a joint association exceeded 0.5 
(Supplementary Table 6). Of these, 45 were iPSC-specific, including PTPN2, an iPSC-
specific eQTL that strongly colocalised with risk variants for four autoimmune disorders 
(Fig. 5a). Previous eQTL studies in both immune cells30–32 and GTEx tissues have not 
identified a PTPN2 eQTL (Extended Data Fig. 9), suggesting that disease risk variants at 
PTPN2 may function in stem cells, or early development.
Statistical colocalisation analysis is limited to instances where full summary statistics are 
available for both traits. For other disease traits available in the GWAS catalogue, we 
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searched for sharing of lead iPSC-specific eQTL and GWAS SNPs. We found six variants 
where the lead eQTL variant was identical to a catalogued GWAS variant, with no other 
common variants in LD (r2 < 0.8). One example was rs10069690, the lead eQTL variant for 
the TERT (Telomerase Reverse Transcriptase) gene (Fig. 5b). Although this variant is 
associated with germline predisposition to seven cancers33–35, this eQTL is not reported in 
cancer eQTL studies36–38 nor in any GTEx tissue. Previous studies have reported aberrant 
splicing of TERT caused by rs1006969039. We quantified TERT intron retention rates and 
found that the minor allele of rs10069690 increased the fraction of TERT transcripts in 
which intron four is retained (P = 1.7x10-9, Bonferroni adjusted) (Fig. 5d, Extended Data 
Fig. 10). Somatic TERT promoter mutations only manifest in differentiated cells, resulting 
in increased telomerase activity40. We speculate that the germline TERT eQTL we 
identified in iPSCs results in genotype-dependent variability in telomerase activity in 
somatic cell types, leading to differential cancer susceptibility.
Discussion
Here we present the most comprehensive analysis yet of genetic and phenotypic data from 
human iPSC lines. Our study substantially extends on previous work6,7 by demonstrating 
widespread functional consequences of genetic variation for many molecular and cellular 
phenotypes in human pluripotent stem cell lines, including in the efficiency with which iPS 
cells differentiate41–43. This is potentially a consequence of variation in core components 
of the regulatory networks controlling cellular differentiation and responses to external 
environmental stimuli, as observed previously in hematopoietic cells and mouse and fly 
embryos44–46.
We have also created a high-resolution map of recurrent genetic abnormalities in hiPSCs and 
identified plausible candidate targets of selection. The majority of these recurrent loci are 
rare and were not reliably identified in previous studies with smaller sample sizes. 
Compared to previous work11,12, we observed substantially lower levels of genetic 
aberrations. One possible explanation is that access to donor-matched reference samples 
helped us more accurately identify germline CNAs that would otherwise have inflated our 
estimates, while previous studies in ESCs were unable to perform similar comparisons.
Our study provides the highest resolution map to date of common regulatory variation in 
human PSCs. We show that variation in local gene regulation in iPSCs is similar to that in 
somatic tissues, with eQTLs driving cell-type specific expression profiles through distal 
tissue-specific regulatory elements. We have identified eQTLs that function primarily in 
pluripotent cells, a subset of which tag loci associated with disease. These loci may drive 
disease-susceptibility through molecular changes early in development or, more generally, in 
cells with ‘stem-like’ characteristics, which are not well captured by studies of differentiated 
primary tissues from adult individuals. A compelling example of this is the iPSC-specific 
eQTL regulating TERT expression. In human tissues, telomerase activity is mainly restricted 
to stem cells, with most somatic tissues silencing TERT expression. However, cancer cells 
bypass this tumour suppressive mechanism by reactivating telomerase activity47. This result 
highlights how iPSCs could be used to study the genetic effects of diseases that manifest in 
transient states during cellular growth and differentiation, including in cancer48.
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The analysis of the recurrence of CNAs and the eQTL map we present are based on a large 
sample, providing a high-confidence map of molecular associations in iPSCs. We have 
presented preliminary experimental characterisation of some of the CNAs and eQTLs we 
detected, however our results are inconclusive. An important next step will be to perform 
more extensive functional characterisation to understand how iPSC cellular phenotypes are 
influenced by CNAs and iPSC eQTLs. We anticipate that the lines and data we have 
generated here will be a valuable starting point for future studies to understand how 
germline and somatic genetic variation influences iPSC growth and differentiation.
In summary, our study provides a detailed picture of the genetic and phenotypic variability 
in human pluripotent stem cells, including the major drivers of this variation. Data and cell 
lines from this study are being made available through www.hipsci.org, the European 
Collection of Authenticated Cell Cultures (ECACC) and the European Bank for Induced 
Pluripotent Stem Cells (EBiSC). As the HipSci resource continues to expand in sample size 
and assays, it will enable the study of subtler genetic effects, under a wider range of 
conditions, in an increasing range of disease-relevant differentiated cell types.
Methods
Generation of iPSC lines
All samples for the HipSci resource were collected from consented research volunteers 
recruited from the NIHR Cambridge BioResource (http://
www.cambridgebioresource.org.uk). Samples were collected initially under ethics for iPSC 
derivation (REC Ref: 09/H0304/77, V2 04/01/2013), with later samples collected under a 
revised consent (REC Ref: 09/H0304/77, V3 15/03/2013).
Fibroblast isolation—Primary fibroblasts were derived from 2 mm skin punch biopsies 
from each donor. Biopsies were collected in fibroblast growth medium (Advanced DMEM, 
10% FBS, 1% L-Glutamine, 0.007% 2-mercaptoethanol and 1% Pen/Strep) in falcon tubes 
at room temperature. Biopsies were manually dissected using a microscope under a drop of 
fibroblast medium using sterile scalpels. The biopsy fragments were transferred onto a 60 
mm Petri dish containing several drops of fibroblast growth medium. Sterile cover slips were 
placed onto the dissected pieces of tissue to hold them in place against the bottom of the 
plate. The explants were cultured for five days and the spent media was removed and 
replaced with a few drops of media (1 ml) to prevent dehydration. The explants were fed 
every five days with 1 ml fibroblast media until fibroblast outgrowths appeared. The 
explants were screened for presence of mycoplasma using a standard PCR kit (EZ-PCR Kit, 
Gene flow (41106313-001)). On average outgrowths appeared within 14 days, with a small 
fraction of samples failing to produce outgrowths (12% of cases). Failures were due to 
contamination (0.5%) or lack of observed outgrowths after 30 days (11%). Approximately 
30 days post dissection, when the fibroblasts had reached confluence, the culture was 
trypsinized and passaged into a 25 cm2 tissue culture flask. When 80-90% confluent, the 
fibroblasts were further passaged into a 75 cm2 flask. Cells were then expanded to 
confluency in 225 cm2 flasks (at a split ratio of 1:3) and either cryopreserved at 1-2 million 
cells per vial in FBS and 10% DMSO or seeded immediately for reprogramming.
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iPSC derivation—Fibroblasts were transduced in one well of a six-well plate using Sendai 
vectors expressing hOCT3/4, hSOX2, hKLF4, and hc-MYC 50 (CytoTune™, Life 
Technologies, Cat. no. A1377801). The transduced cells were cultured on an irradiated 
mouse embryonic fibroblast (MEF-CF1) feeder layer on a 10 cm2 tissue culture dish in iPSC 
medium consisting of Advanced DMEM (Life technologies, UK) supplemented with 10% 
Knockout Serum Replacement (KOSR, Life technologies, UK), 2 mM L-glutamine (Life 
technologies, UK) 0.007% 2-mercaptoethanol (Sigma-Aldrich, UK), 4 ng/mL of 
recombinant Zebrafish Fibroblast Growth Factor-2 (CSCR, University of Cambridge), and 
1% Pen/Strep (Life technologies, UK). Cells with an iPSC morphology appeared 
approximately 25 to 30 days post-transduction. The undifferentiated colonies (six per donor) 
were picked between days 30-40, transferred onto 12-well MEF-CF1 feeder plates and 
cultured in iPSC medium with daily media change until ready to passage. Cells were 
passaged every five to seven days, depending on the confluence and morphology of the cells, 
at a maximum 1:3 split ratio until established – usually at passage five or six. Once the iPSC 
lines were established in culture, three of the six lines were selected based on morphological 
qualities (undifferentiated, roundness and compactness of colonies) and expanded for 
banking and characterisation.
Transfer to feeder-free culture—Between passages four to eight, selected feeder-
dependent iPSC lines were transferred to feeder-free culture. The feeder-dependent iPSC 
lines were split and passaged onto both feeder-dependent and feeder-free conditions. The 
feeder dependent lines continued to be cultured on MEF-CF1 feeder plates in iPSC medium, 
whilst the feeder free lines were cultured in Essential 8 (E8) medium on tissue culture dishes 
coated with 10 µg/ml Vitronectin XF (StemCell Technologies, UK, 07180). E8 complete 
medium consists of basal medium DMEM/F-12(HAM) 1:1(Life technologies, UK, 
A1517001) supplemented with E8 supplement (50X) (Life technologies, UK, A1517001) 
and 1% Pen/Strep (Life technologies, UK, 15140122). Media was changed daily. To passage 
feeder-free iPSC lines, cells were washed with PBS and incubated with PBS-EDTA solution 
(0.5 mM) for 5-8 minutes. PBS-EDTA solution was removed, and cells were resuspended in 
E8 medium and seeded at split ratios ranging from 1:3 to 1:6 onto Vitronectin coated tissue 
culture dishes. Cells were passaged every four to seven days (depending on the confluence 
and morphology of the cells). Once the feeder-free iPSC lines were established in culture, 
the cells were expanded for banking and characterisation.
iPSC line selection and molecular assays—Each iPSC line was passaged on average 
16 times before being expanded for the collection of initial molecular data for quality 
control (‘Tier 1 assays’). These included genotyping (‘gtarray’), gene expression data 
(‘gexarray’), and an assessment of the pluripotency and differentiation potential of each line 
(‘Cellomics’). Pluripotency of the lines was additionally verified in silico, using the 
PluriTest assay 9. Following Tier 1 assays, one or two lines were selected from a subset of 
donors (hereafter ‘selected lines’) and further expanded to enable collection of a richer set of 
molecular data (‘Tier 2 assays’). The criteria for line selection were: (i) level of pluripotency, 
as determined by the PluriTest assay (ii) number of copy number abnormalities and (iii) 
ability to differentiate into each of the three germ layers. These included proteomics, DNA 
methylation (‘mtarray’), RNA-sequencing and high-content cellular imaging. Once Tier 1 
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genotyping data were collected (see below) cell lines originating from the same donor were 
checked for possible sample swaps using BCFtools (bcftools gtcheck -G1).
Nucleic acid extraction
DNA and RNA from iPSC lines were extracted using Qiagen Chemistry on a QIAcube 
automated extraction platform. Sample volume was checked using a BioMicroLab 
automated volume check system. The PicoGreen assay was used to measure the 
concentration of the samples, using both Beckman FX liquid handling platforms and 
Molecular Devices plate readers. Invitrogen E-Gels were run to check sample integrity; the 
loading of these gels was automated using Beckman FX/NX liquid handling platforms. A 
standard Fluidigm genotyping assay containing 24 SNPs (22 autosomal and 2 gender 
markers) was performed to produce a fingerprint of the samples, which was used to confirm 
sample identity after sequencing or genotyping. The gender markers also allowed for sample 
swaps and plate orientation issues to be identified prior to downstream analysis. Samples 
that passed quality control were quantified to 50 ng/µl by the onsite sample management 
team prior to submission for sequencing.
Genotyping (‘gtarray’)
Experimental processing of arrays—Samples were hybridised to the Illumina 
HumanCoreExome-12 Beadchip according to the manufacturer's guidelines. Four 
microlitres (200 ng) of DNA is required for the pre-amplification reaction using a Tecan 
Freedom Evo. The process is automated except for manual agitation/centrifugation step 
midway through and at the end of the process. Post-amplification processes (fragmentation, 
precipitation, resuspension, hybridization to beadchip and xStaining) were completed over 
three days as per Illumina protocol. Following the staining process, beadchips were coated 
for protection and dried completely under vacuum before scanning on the Illumina iScan 
paired with Illumina Autoloader 2.x. Prior to downstream analysis, all samples were 
subjected to initial quality control to establish that the assay was successful. Sample call-
rates below 92.5% were flagged before loading samples into Illumina’s GenomeStudio 
software. Using Illumina’s QC dashboard, sample performance was assessed by measuring 
dependant and non-dependent controls that are manufactured onto each beadchip during 
production.
Genotype calling and imputation—After primary quality control, the Genotyping (GT) 
module of the GenomeStudio software (Illumina, CA, USA) was used to call the genotypes. 
For each probe, the GT module estimates the Log R ratio and B-allele frequency for each 
sample using a clustering model applied to the distribution of signal intensities. These 
statistics are used internally by GenomeStudio to assign the sample genotypes for each 
marker. Variant coverage was further increased using statistical imputation and phasing. We 
constructed a reference panel of haplotypes from a combination of SNPs and small 
insertions and deletions (indels) in the UK10K cohorts and 1000 Genomes Phase 1 data 
51,52. Samples were independently imputed using IMPUTE2 v2.3.1 53 and subsequently 
phased using SHAPEIT v2.r790 54. This analysis was done in chunks of average 5 Mb, with 
300 Kb buffer regions on each side. IMPUTE2 was used with its default MCMC options (-
Ne 20000 -k 80) for autosomes and -Ne 15000 -k 100 for X chromosome. SHAPEIT was 
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run without MCMC iteration (-no-mcmc) so that each sample was phased independently 
using the reference panel as the haplotype scaffold regardless of the phasing of the other 
samples. Single-sample VCFs were merged together and INFO scores were re-calculated 
from genotype posterior probabilities (GPs). Variants with INFO score less than 0.4 were 
excluded from further analysis. Cell lines originating from the same donor were checked for 
possible sample swaps using BCFtools (bcftools gtcheck -G1). Swapped samples typically 
had large number of discordant genotypes (>20%), whereas in samples from the same donor 
the number of discordant genotypes was low (<0.3%), even in the presence of large copy 
number variation.
Gene expression arrays (‘gexarray’)
Experimental processing of arrays—500 ng of total RNA for each sample was 
amplified and purified using the Illumina TotalPrep-96 RNA Amplification kit (Life 
Technologies, UK), according to the manufacturer’s instructions. Biotin-Labelled cRNA was 
then normalized to a concentration of 150 ng/ul and 750 ng was hybridised to Illumina 
Human-12 v4 BeadChips (Illumina, CA, USA) for 16 hours (overnight) at 58°C. Following 
hybridisation, BeadChips were washed and stained with streptavidin-Cy3 (GE Healthcare, 
UK). BeadChips were then scanned using the BeadArray reader and image data was then 
processed using GenomeStudio software (Illumina, CA, USA).
Re-mapping of array probes—Prior to analysis, array probe sequences (Nprobes = 
47,230; length 50 bp) were re-mapped against the human genome build 37 using BWA 
version 0.7.5 55.
We first mapped the sequences allowing no mismatches (-n 0, seeding disabled) and kept 
uniquely mapping probes with a minimum mapping quality (MAPQ) of 10 (–q 10). These 
sequences were then mapped again, this time allowing one mismatch (-n 1). Again, only 
uniquely mapping probes with MAPQ > 10 were retained, resulting in a total of N = 37,740 
probes. We further removed all probes that overlapped with any variant with a minor allele 
frequency greater than 0.05 in the main imputed dataset (Nlines = 858). Remaining probes 
were annotated with Gencode version 19 gene annotations 56 and only probes mapping 
uniquely to a single gene were kept (final probeset Nprobes = 25,604, representing 17,116 
unique genes of which 14,569 are protein coding.
Pre-processing and normalization of data—Gene expression profiles were measured 
with Illumina HumanHT-12 v4 Expression BeadChips. After limiting the dataset to iPSC 
lines derived from fibroblast of healthy donors, we obtained data from 711 iPSC lines and 
301 somatic fibroblast lines. Probe intensity estimates were normalised separately for the 
two cell types using the variance-stabilizing transformation implemented in the R/
Bioconductor vsn package 57. After normalization, the datasets were limited to the final 
remapped set of probes (Nprobes= 25,604). We refer to this version of the “gexarray” data by 
vsn log2 (iPSC/somatic).
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Cellular differentiation assay (‘Cellomics’)
Differentiation potential assay—Selected iPSC lines were assessed for their 
pluripotency and differentiation properties by culturing the cells under conditions favouring 
the formation of the three embryonic germ layers, and subsequent immunostaining with 
markers specific for pluripotency and differentiation. Differentiation was performed as 
described previously 58. Briefly, iPSCs grown in feeder-dependent or feeder-free conditions 
were harvested using either collagenase and dispase or EDTA, respectively. Colonies were 
collected, washed in media and mechanically broken up before being re-plated onto 24-well 
mouse embryonic fibroblast (MEF) feeder plates or pre-coated gelatine/FBS plates. For 
pluripotency assays, feeder-dependent colonies were seeded on MEF feeder plates and 
feeder-free colonies onto Vitronectin plates. For the differentiation assay, colonies were 
grown on gelatine/FBS plates. Prior to differentiation to mesoderm (dME), endoderm (dEN), 
and neuroectoderm (dEC), cells were cultured overnight in pre-differentiation media CDM-
PVA supplemented with recombinant Activin-A (10 ng/ml; CSCR, University of 
Cambridge) and zebrafish FGF2 (12 ng/ml; CSCR, University of Cambridge).
For differentiation into mesoderm following culture in pre-differentiation media, spent 
media was removed and replaced with fresh CDM-PVA media containing bone morphogenic 
protein 4 (BMP4, 10 ng/ml, R&D Systems Inc.), FGF2 (20 ng/ml; CSCR, University of 
Cambridge), recombinant Activin-A (10 ng/ml; CSCR, University of Cambridge), LY29004 
(10 mM, Promega, UK.), CHIR99021 (5 mM, Selleckchem) and subsequently cultured for 
three days. Media was changed daily.
For differentiation into endoderm, following culture in pre-differentiation media cells were 
further cultured in differentiation media for three days. Briefly, day one media was removed 
and replaced with fresh CDM-PVA media supplemented with recombinant Activin-A (100 
ng/ml; CSCR, University of Cambridge), zebrafish FGF2 (80 ng/ml; CSCR, University of 
Cambridge), BMP4 (10 ng/ml R&D Systems Inc.), LY29004 (10 mM), and CHIR99021 (3 
mM). Day two media was removed and replaced with fresh CDM-PVA supplemented with 
recombinant Activin-A (100 ng/ml), zebrafish FGF2 (80 ng/ml), BMP4 (10 ng/ml), and 
LY29004 (10 mM). Day three media was removed and replaced with RPMI media 
supplemented with B27 (1x, Life Technologies UK), recombinant Activin-A (100 ng/ml), 
zebrafish FGF2 (80 ng/ml), and Non-Essential Amino Acids (1x, Life Technologies UK).
For differentiation to neuroectoderm, iPSCs were grown for 12 days in CDM-PVA 
supplemented with SB431542 (10mM; Tocris Bioscience), FGF2 (12 ng/ml, CSCR 
University of Cambridge), and Noggin (150 ng/ml, R&D Systems Inc.). Media was changed 
daily.
Immunostaining for pluripotency and differentiation markers—For the detection 
of pluripotency and differentiation markers, cells grown in 24-well plates were fixed with 
4% paraformaldehyde for 20 minutes. Cells were permeabilized and blocked with 10% 
donkey serum and 0.1% Triton X-100 in PBS. Subsequently, cells were stained with primary 
antibodies overnight at 4°C and finally incubated with fluorochrome-labeled secondary 
antibodies (Invitrogen, UK). The primary antibodies used for detecting pluripotency markers 
were: anti-OCT4 (SC-5279, Santa Cruz Biotech, USA), anti-SOX2 (AF2018, R&D, UK), 
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anti-NANOG (AF1997, R&D, UK). The primary antibodies used for detecting endoderm 
markers were: anti-SOX17 (AF1924, R&D, UK), anti-CXCR4 (MAB173-100, R&D, UK 
and anti-GATA4 (SC-25310, Santa Cruz Biotech, USA). The primary antibodies used for 
detecting mesoderm markers were: anti-Brachyury (AF2085, R&D, UK), anti-EOMES 
(Ab23345, Abcam, UK) and anti-MIXL1 (SC-98664, Santa Cruz Biotech, USA). The 
primary antibodies used for detecting neuroectoderm markers were: anti-NESTIN 
(AB22035, Abcam, UK), and anti-SOX1 (AF3369, R&D, UK) anti-SOX2 (AF2018, R&D, 
UK). The secondary antibodies used were: Donkey anti-goat AF488 (Invitrogen, UK), 
Donkey anti-mouse AF488 (Invitrogen, UK), Donkey anti-rabbit AF488 (Invitrogen, UK). 
Additionally, DAPI staining was used to label cell nucleus in order to facilitate cell 
segmentation.
Images were captured and quantified using a Cellomics Array Scan imaging system. Briefly, 
images were taken in 24-well plates. Individual plates were used to either measure 
pluripotency markers or markers to assess differentiation for one of the germ layers. Each 
plate contained cells from one or two cell lines, as well as technical replicates for each 
measurement. Three types of plate layouts were considered throughout the project: Two-
channel, three-channel, and three-channel with single staining. For all layouts, the signal 
from the DAPI staining was read in the first channel. The first columns of each plate were 
used for marker staining; subsequent columns (one or two) were stained with the secondary 
antibody to measure background signal (Extended Data Fig. 1).
Processing of images on the Cellomics instrument—Individual wells in the plate 
were imaged consecutively, either until the whole plate was imaged or until 10,000 
individual cells were detected. Cell detection was performed based on nucleus segmentation 
from DAPI staining. All considered markers except for CXCR4 are nuclear markers, so their 
signal intensities were measured in the segmented nucleus area. The cell surface marker 
CXCR4 was quantified in a circle around the segmented nucleus. For each cell and marker, 
we used the average intensity within the respective quantification area as final readout. Each 
batch of lines for staining included the reference line (‘CTRL0214pf-iely’). This reference 
line was used to determine parameter values for cell size (usually around 30-400) and an 
approximate intensity threshold for detecting responding cells.
To quantify Cellomics phenotypes, we fit a Gamma mixture model to the Cellomics raw 
intensities (Supplementary Information). Briefly, this model was fit to primary wells as well 
as background wells (Extended Data Fig. 1), thereby estimating both the proportion of 
responding cells as well as the overall intensity (expression) of the corresponding cells.
For downstream analyses, technical replicates on each plate were aggregated using average 
values. Analogously to the processing steps for gene expression arrays, we regressed out 
batch (derived from the date of staining), media type, gender, passage number, plating 
technician, fixation technician, and the technician in charge of the staining. Analyses of 
proportions of responding cells are based on estimates of the proportion of responding cells 
(Fig. 1c,d). Analyses that consider intensities were based on quantitative expression 
estimates, averaged across individual markers for a given layer (Extended Data Fig. 1c).
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Proteomics
Sample preparation—Frozen iPSC pellets were thawed and washed with PBS twice prior 
to lysis. The protein content of the cells was extracted by re-dissolving the pellets in 8 M 
urea, 100 mM TEAB, pH 8.5 and mixing at room temperature for 15 minutes. Next, the 
DNA content of the cells was sheared using ultrasonication. The protein amount was 
determined using a fluorescence based assay (EZQ, Life Technologies) prior to double 
digestion using mass spectrometry grade lysyl endopeptidase (Wako, Japan) and trypsin 
(Pierce) in a substrate-to-enzyme ratio of 1:50; w:w, at a final urea concentrations of 2 M 
and 0.8 M, respectively. The digested proteins were desalted using sepak vacuum cartridges 
(waters) and dried in vacuo. The desalted peptides were redissolved in (10 mM borate at pH 
9.3 : acetonitrile; 80:20; v:v) for hSAX fractionation using a 40 minute gradient. A total of 
16 fractions were collected, desalted and dried. The hSAX fractions were redissolved in 5% 
formic acid for label-free LC-MS analysis. In addition to individual samples, a composite 
reference sample (‘HPSI_composite_1503’) was constructed by pooling together protein 
lysates from 43 iPSC lines. 2 mg of protein was used for each. All samples in this reference 
were of fibroblast origin and reprogrammed with sendai virus.
For Tandem Mass Tag (TMT)-based quantification, the dried peptides were re-dissolved in 
100mM TEAB (50 µL) and their concentration was measured using a fluorescent assay 
(CBQCA) (Life Technologies). 100 µg of peptides from each cell line to be compared, in 
100 µL of TEAB, were labelled with a different TMT tag (20 µg ml-1 in 40 µL acetonitrile) 
(Thermo Scientific), for two hours at room temperature. After incubation, the labelling 
reaction was quenched using 8 µl of 5% hydroxylamine (Pierce) for 30 minutes and the 
different cell lines/tags were mixed and dried in vacuo.
The TMT samples were fractionated using off-line high pH reverse phase chromatography: 
samples were loaded onto a 4.6 x 250 mm Xbridge™ BEH130 C18 column with 3.5 µm 
particles (Waters). Using a Dionex bioRS system, the samples were separated using a 25-
minute multistep gradient of solvents A (10 mM formate at pH 9) and B (10 mM ammonium 
formate pH 9 in 80% acetonitrile), at a flow rate of 1 ml/min. Peptides were separated into 
48 fractions, which were consolidated into 24 fractions. The fractions were subsequently 
dried and the peptides re-dissolved in 5% formic acid and analysed by LC-MS.
LC-MS/MS
Label-free analysis: RP-LC was performed using a Dionex RSLC nano HPLC (Thermo 
Scientific). Peptides were injected onto a 75 μm × 2 cm PepMap-C18 pre-column and 
resolved on a 75 μm × 50 cm RP- C18 EASY-Spray temperature controlled integrated 
column-emitter (Thermo) using a four-hour multistep gradient from 5% B to 35% B with a 
constant flow of 200 nL min-1 as described previously 59,60. The mobile phases were: 2% 
ACN incorporating 0.1% FA (Solvent A) and 80% ACN incorporating 0.1% FA (Solvent B). 
The spray was initiated by applying 2.5 kV to the EASY-Spray emitter and the data were 
acquired on a Q-Exactive Orbitrap (Thermo Scientific) under the control of Xcalibur 
software in a data dependent mode selecting the 15 most intense ions for HCD-MS/MS.
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TMT-based analysis: 5% of the material was analysed using an orbitrap fusion tribrid mass 
spectrometer (Thermo Scientific), equipped with a Dionex ultra high-pressure liquid 
chromatography system (nano RSLC). RP-LC was performed using a Dionex RSLC nano 
HPLC (Thermo Scientific). Peptides were injected onto a 75 μm × 2 cm PepMap-C18 pre-
column and resolved on a 75 μm × 50 cm RP- C18 EASY-Spray temperature controlled 
integrated column-emitter (Thermo), using a four-hour multistep gradient from 5% B to 
35% B with a constant flow of 200 nL min-1. The mobile phases were: 2% ACN 
incorporating 0.1% FA (Solvent A) and 80% ACN incorporating 0.1% FA (Solvent B). The 
spray was initiated by applying 2.5 kV to the EASY-Spray emitter and the data were 
acquired under the control of Xcalibur software in a data dependent mode using top speed 
and 4 s duration per cycle. The survey scan is acquired in the orbitrap covering the m/z range 
from 400 to 1400 Th, with a mass resolution of 120,000 and an automatic gain control 
(AGC) target of 2.0 e5 ions. The most intense ions were selected for fragmentation using 
CID in the ion trap with 30 % CID collision energy and an isolation window of 1.6 Th. The 
AGC target was set to 1.0 e4 with a maximum injection time of 70 ms and a dynamic 
exclusion of 80 s.
During the MS3 analysis for more accurate TMT quantifications, 5 fragment ions were co-
isolated using synchronous precursor selection using a window of 2 Th and further 
fragmented using HCD collision energy of 55%. The fragments were then analysed in the 
orbitrap with a resolution of 60,000. The AGC target was set to 1.0 e5 and the maximum 
injection time was set to 105 ms.
Quantification—Label-free proteomics samples were analysed with MaxQuant v. 1.3.0.5 
software 61 as a single batch against a Uniprot reference database, constructed from all 
Swissprot entries (N = 20,043) and their isoforms (N = 21,914). Run parameters have been 
deposited to PRIDE along with the data and the full MaxQuant quantification output 
(PXD003903).
For the selected TMT-based experiments (Extended Data Fig. 5b), the TMT-labelled samples 
were analysed using Maxquant v. 1.5.3.30. Proteins and peptides were identified using the 
UniProt human reference proteome database (Swiss Prot). Run parameters have been 
deposited to PRIDE along with the full MaxQuant quantification output (PXD005506).
Pre-processing and normalization of data—Data for analysis was obtained from the 
“ProteinGroups.txt” output of MaxQuant. Contaminant and reverse hits (N = 3,419) were 
excluded from analysis. For each sample, the total protein abundance was calculated by 
summing up protein intensity (‘Intensity’) values across all proteins and protein groups. This 
value was then used to scale all quantification values (‘iBAQ’) per sample. For a protein or a 
protein group to be considered, we required at least one unique peptide mapping to it. 
Overall, we quantified 10,097 protein groups (4,877 unique proteins) in at least one of the 
samples. Only unique protein entries quantified in at least half of the samples were used in 
the subsequent analyses (3,435 proteins). The mean pair-wise correlation of samples was 
0.87 for unique proteins (Spearman rank correlation). Based on the clustering of samples 
(principal component analysis and pairwise correlation of protein quantification; data not 
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shown), one sample appeared as an outlier (‘HPSI0713i-darw_1’) and was excluded from 
further analyses.
DNA methylation (‘mtarray’)
Sample preparation and experimental processing of arrays—500 ng of DNA was 
used for bisulfite conversion using the Zymo Research EZ-96 DNA Methylation Kit. The 
bisulfite converted DNA extracts were hybridized to Infinium 450K BeadChips (Illumina). 
Due to the differences in sample plates between the completed Zymo assay and the Illumina 
assay, pre-amplification was performed manually by following the Illumina MSA4 SOP. 
Once complete, sample and reagent barcodes were simmed through the Illumina LIMS 
tracking software. Four microlitres (200 ng) of sample is required (Illumina guidelines) for 
the pre-amplification reaction using the Tecan Freedom Evo. No further quantification step 
was performed after the completion of the Zymo assay. Labelling was performed 
automatically during the post-amplification xStain process with Biotin and DNP labelled 
antibodies. The HumanMethylation450_15017482_v.1.1 arrays were scanned with iScan 
(Illumina) in accordance with the manufacturer’s protocol.
Quantification and normalization of data—Methylation profiles were measured with 
HumanMethylation450_15017482_v.1.1 arrays. GenomeStudio v2011.1 (Methylation 
Module 1.9.0; Illumina) was used to export the raw data as. idat files, which were then 
processed with the minfi Bioconductor package 62. Samples were normalised using the 
stratified quantile normalisation implemented in the ‘preprocessQuantile’ function and 
probes were annotated to genomic locations using the 
IlluminaHumanMethylation450kanno.ilmn12.hg19 Bioconductor annotation package. 
Subsequently, genotyping probes or probes overlapping any dbSNP or 1000 Genomes 
variant loci were discarded. M-values, defined as the logarithm of the fraction of the 
methylated and unmethylated channels M = log( Meth / Unmeth ), were used in the variance 
component and other downstream analysis.
RNA-sequencing
Library preparation and sequencing—mRNA in total RNA was isolated and 
converted into non-stranded or stranded libraries. Non-stranded libraries were produced 
manually using reagents provided in the Illumina TruSeq RNA Sample Preparation Kit v2 in 
accordance with manufacturer’s recommendations. The protocol was modified to produce 
size-selected libraries by modifying the fragmentation conditions and using a Caliper 
LabChip XT instrument. Stranded libraries were prepared using a NeoPrep Library Prep 
System and the reagents provided in the Illumina TrueSeq Stranded mRNA Library 
Preparation kit. The stranded library prep workflow is similar to the non-stranded workflow, 
except that it involves additional ribosomal reduction chemistry to maximise the percentage 
of uniquely mapped reads. Following purification, the RNA was fragmented and synthesised 
into cDNA using a reverse transcriptase process. The products were then enriched with PCR 
(maximum 10 cycles) to create the final cDNA library. Enriched libraries were subjected to 
75 base paired-end sequencing using Illumina HiSeq 2000 v3 kits following manufacturer’s 
instructions.
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Pre-processing of sequence data—Raw RNA-seq reads were aligned using STAR 
v2.4.0 63 against the 1000 Genomes Phase2 reference genome assembly that integrates the 
GRCh37 primary assembly with the human decoy sequence 37d5. Exon-intron junctions 
derived from Gencode v19 transcript annotations 56 were used to improve the alignments.
The same approach was taken to re-align data for two tissues from the GTEx Project 
(Extended Data Fig. 8). Raw fastq-files were obtained from dbGap (accession 
phs0004242.v6.p1.c1) for Adrenal Gland (N=126 samples) and Esophagus 
Gastroesophageal Junction (N=127 samples; limited to 126 unique samples used in the 
GTEx V6p map).
Quantification and normalization of data—Mapped reads were quantified on the level 
of genes using HTSeq version 0.6.1p1 64 and annotations from Gencode v19 56. We used 
the ‘union’ method of ‘htseq-count’ for unstranded libraries (-s no) and considered only 
uniquely mapping reads (-a 255; with 255 indicating uniquely mapped reads from the STAR 
aligner). Of note, STAR only outputs properly paired reads. Raw gene counts were scaled 
across individuals with scaling factors obtained with DESeq 65. The same approach was 
used to generate ‘probe-level’ counts using the final re-mapped set of gexarray probes. 
These were used to filter expressed probes in the CNA analysis. Finally, an alternative set of 
gene-level quantifications was generated for quality control purposes using RNA-SeQC 
v1.1.8 66. To match the original GTEx v6p quantifications as closely as possible, we ran 
RNA-SeQC with the -strictMode flag and used custom exon annotations generated and used 
by GTEx (gencode.v19.genes.v6p_model.patched_contigs.gtf.gz) to obtain gene RPKMs. 
The same RNA-SeQC quantification pipeline was applied to the two re-mapped GTEx 
tissues.
High-content cellular imaging
Sample preparation and cellular imaging—Each line was cultured and plated as 
previously described 67. Briefly, 96-well plates were coated with three concentrations of 
Fibronectin in alternated columns in a randomised fashion. Cell lines were seeded also in 
rows in a randomised fashion. 3,000 cells were plated and fixed after 24 hours. EdU was 
incorporated 30 minutes before fixation. Plates were then fixed and stained with DAPI and 
cell mask and EdU staining. Images were acquired using the Operetta (Perkin Elmer) high 
content device. Using the Harmony software, measurements were derived for each cell. 
Measurements included intensity features (DAPI, EdU), morphology features (cell area, cell 
roundness, cell width to length ratio, nucleus area, nucleus roundness, nucleus width to 
length ratio) and context features related with cell adhesion properties (number of cells per 
clump). Processing quantification and normalization of data was performed as previously 
described 67. The Cellomics fluorescence imaging data was used to quantify the fraction of 
cells expressing each protein marker independently. In the absence of co-staining 
information we sought to use the marginal fractions of cells expressing each marker to 
calculate lower and upper bounds for the fractions of cell estimating all markers 
simultaneously. Let be the fraction of cells expressing protein marker and the fraction of 
cells expressing all n markers simultaneously, then this value is bounded by:
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Variance component analysis—Feature (gene, protein, or probe) intensity estimates for 
each of the assays were pre-processed and normalised as described in the individual assay 
sections and subsequently transformed into a standard normal distribution across lines. For 
each feature in each assay, variance was partitioned using a linear mixed model 
(implemented in the lme4 R package) fitted with all metadata variables as random effects. 
Only lines with complete metadata information were included in each one of the analyses, 
these numbers are shown in parenthesis in Fig. 3a-c. The variance components were 
normalized to sum to one and subsequently averaged across the different sets of features 
considered (Fig. 3). The fraction of non-technical variance explained by each biological or 
experimental factor refers to the variance explained by the factor, divided by the total 
variance minus the variance explained by assay batches (see below for a definition of 
experimental and assay batch factors). Confidence intervals for the Cellomics variance 
components were obtained with the ‘profile’ method implemented in the ‘confint’ function 
of the lme4 package. The following random effects were included for each assay:
• Methylation - Donor. Experimental factors (summed up to produce Fig. 3a): 
gender, passage interval at time of assay. Assay batches (summed up to produce 
Fig. 3a): sentrix id, sentrix array (within sentrix id), bisulfite conversion plate, 
year and month of assay, year and month of Tier 1 assays.
• Expression microarrays - Donor. Experimental factors: gender, passage interval 
at the time of assay, culture system at time of assay, trisomy status, recurrent 
CNA status. Assay batches: array batch, year and month of assay, beachip id, 
beadchip array (within beadchip id), technician id, assay performed before or 
after April 2014.
• RNA-seq - Donor. Experimental factors: gender, passage interval at time of 
assay, trisomy status, recurrent CNA status, culture system at time of assay. 
Assay batches: year and month of assay, year and month of Tier 1 assays.
• Proteomics (uniquely identified proteins) - Donor. Experimental factors: gender. 
Assay batches: year and month of QC assays, instrument, year and month of 
analysis.
• Cellomics - Donor. Experimental factors: gender, culture system at the time of 
assay, passage interval at time of assay. Assay batches: date of staining, plating 
technician id, fixation technician id, staining technician id, primary antibody lot 
and secondary antibody lot.
• Cellular morphology assays (cell area, roundness, EDU, PC1 cellmorph) - 
Donor. Experimental factors: gender, cell line, fibronectin concentration. Assay 
batches: plate, row.
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CNA analysis
Pairwise fibroblast-iPSC CNA detection—Copy number differences between 
fibroblast and iPSC lines from the same donor were checked using a HMM algorithm 
implemented in BCFtools/cnv for this purpose 10. In order to distinguish between normal 
and novel copy number variation as well as to reduce the number of false calls, the program 
was run in the pairwise mode (bcftools cnv -c <donor> -s <derived>) with default 
parameters. The CNA calls were filtered to exclude calls with quality score smaller than 2, 
deletions with fewer than 10 markers, and duplications with fewer than 10 heterozygous 
markers. Three sets of CNA calls were generated: a more lenient set containing all calls >= 
0.2 Mb in length, a set with all calls >= 0.5 Mb and a stricter subset of the previous with 
calls >= 1 Mb.
Statistical significance of recurrent CNAs was estimated from the complementary 
cumulative distribution function of the binomial distribution, and the significance of sub-
chromosomal events was estimated using a permutation test (Supplementary Information).
Overlap with annotated regions—To assess the significance of the overlap between 
CNAs and annotated regions (namely chromatin fragile sites 16 and recurrent somatic copy 
number altered regions in cancer 68 we randomly generated a set of 2,000 matched control 
regions for each CNA. Control regions were generated so that they had the same size as the 
CNA, did not overlap with telomeres or centromeres, and did not overlap the original CNA. 
Overlaps were determined between the CNA and the annotated regions and between the 
matched control regions and the annotated regions to calculate an empirical P-value.
Association between CNAs and gene expression—To determine the functional 
consequence of CNAs with regards to gene expression we first selected CNAs for which five 
(~1%) or more of the cell lines had a copy number different from two (regardless of copy 
number in the corresponding somatic cells). For each of these CNAs we took the copy 
number at the region of peak coverage for each cell line (see CNA coverage plots in Fig. 2c 
and Extended Data Fig. 4). We then defined the set of expression array probes to test by 
choosing only expressed probes. Here a probe was defined as expressed if the number of 
RNA-seq fragment counts (normalised between samples for sequencing depth) mapping to 
the genomic regions targeted by the probe is greater than 0 in 10% or more of the lines. 
Finally, we used a linear mixed model to independently test for association between copy 
number of each CNA and the intensity of each probe. We included culture condition, gender 
and an interaction between copy number and culture condition as fixed effects; and used 
donor and assay batch as random effects. Q-values were obtained for each CNA using 
Benjamini Hochberg to adjust for multiple testing. The same approach was employed to test 
for association between X chromosome copy number and gene expression, but we limited 
the tests to female samples and to probes on the X chromosome.
Gene set enrichment analysis—Pathway enrichment analysis of the genes regulated by 
chr17 was performed with GSEA 69 on the full list of genes ordered by effects size of 
association between gene expression with copy number and with a custom set of pathways. 
The custom set of pathways considered comprised 1,156 super pathways from the PathCards 
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database 23 filtered to exclude pathways relating to infectious diseases and 
pharmacokinetics. Multiple testing correction was performed as described in 69.
Expression quantitative trait loci (eQTL)
eQTL mapping
Pre-processing of genotype data: Variants in the original VCF files were renamed to 
format “type_chr_pos” (e.g. ‘snp_1_236887241’ or ‘indel:2D_1_18847945’), and filtered 
for polymorphic and bi-allelic sites with VCFtools v.0.1.12b 70 (vcftools –gzvcf IN --mac 1 
--min-alleles 2 --max-alleles 2 --recode --recode-INFO-all –out OUT). The resulting VCF 
files were then converted to ‘012’ format (vcftools --gzvcf IN --012 --out OUT.012), where 
0, 1, and 2 represent the number of non-reference alleles, and further to HDF5 format using 
a converter function (-g012) from LIMIX (). This resulted in a set of N = 14,644,791 variant 
sites. To obtain allele dosages, genotype likelihoods (GL) in the original VCF were 
converted to genotype probabilities (GP) with BCFtools (bcftools +tag2tag IN -O z -o OUT 
-- --gp-to-gl) and used to define allele dosage as follows: Dosage of alternative allele = 
GP(REF/ALT) + 2*GP(ALT/ALT). Genotype dosage information was converted to HDF5 
format using LIMIX converter (LIMIX converter, --g012_dosage). For eQTL mapping, we 
included autosomal variants with a minimum minor allele frequency of 1% in our samples 
and maximum 10% missing values across individuals. Variant sites were further required to 
have a minimum IMPUTE2 INFO score of 0.4 to assure good imputation quality. Missing 
genotypes were mean imputed and the dosage of the alternative allele used for mapping.
Pre-processing of expression data: Scaled gene counts were filtered for missing values 
(maximum 90% missing values, i.e. zero counts, allowed per gene). Zero values were offset 
by 1, after which the data was log10 transformed and quantile normalized across individuals 
using R limma normalizeQuantiles function 71. We then ran PEER 72 with full pre-
normalized dataset with the following parameters: K=30; covariates = gender, iPSC growth 
condition (feeder-dependent/E8), mean expression (‘addMean=True’ in PEER); maximum 
iterations = 10,000. Residuals for each gene were gaussianised, i.e. converted to the 
quantiles of a standard normal distribution and finally mean centered and standardized prior 
to mapping. In total, we had 26,936 and 17,116 genes available for mapping (RNA-seq and 
‘gexarray’, respectively).
Linear mixed model: Expression quantitative trait loci (eQTL) were identified using a 
linear mixed model implemented in LIMIX 73,74. eQTLs were mapped in cis, considering a 
window of 1Mb around the gene start (as defined by Gencode v19 annotations). We 
modelled the genotype as a fixed effect, with population structure included as random effect. 
Population structure was modelled with a kinship matrix, calculated as the dot product of the 
genotypes in trans for each cis window (realized relationship).
eQTL mapping was performed with the following datasets (Supplementary Table 4):
1) iPSC, 166 donors (239 lines), RNA-seq data (hereon the ‘main’ eQTL map)
2) iPSC, 301 donors (711 lines), ‘gexarray’ data
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When multiple lines were available for a donor, the mean expression value of lines was used. 
In the array-based iPSC dataset, which had the largest number of replicate lines available per 
donor (246 donors with multiple lines), we additionally mapped the eQTLs using two 
randomly drawn sets of individual lines per donor to assess the replicability of the iPSC 
eQTLs (Extended Data Fig. 6f-h). In the main RNA-seq based map, we identified both 
primary and secondary eQTL effects. To identify secondary effects, we repeated the 
mapping with the genotypes of the lead eQTL variant included as a covariate in the model. 
Finally, an alternative version of the main eQTL map was generated using a pipeline 
matched with GTEx V6p eQTLs for quality control purposes (See Supplementary 
Information).
Multiple testing correction: For cis eQTLs (primary and secondary), to adjust for multiple 
testing, we permuted genotype sample labels in each cis window 10,000 times, keeping 
everything else in the model constant. To derive an empirical P-value distribution, the test 
statistic of the most significant variant in each permutation round was stored. A region-wise 
adjusted cis P-value was derived from the proportion of permuted test statistics that were 
larger than the most significant observed test statistic in the region. These threshold P-values 
were further adjusted for genome-wide analysis using the Benjamini-Hochberg (BH) 
correction. A gene was considered an eGene if its final BH-adjusted P-value was less than 
0.05.
Identification of tissue-specific cis eQTLs—In this study, tissue-specific eQTLs were 
defined as eQTL effects not replicating in any of the 44 tissues analysed by the GTEx 
Project 24. Replication was tested on the level of individual eQTL variants between all pairs 
of tissues. For this analysis, we considered full cis eQTL output of iPSC eQTLs from HipSci 
and 44 tissues from GTEx (V6p results; 2,025 tissue pairs). The included tissues and cell 
lines are detailed in Supplementary Table 5a. For each discovery tissue, we tested for the 
replication of all lead eQTL effects (lead eQTL variant - target eGene; hereon referred to as 
‘ePair’) originally reported (FDR 5% in both HipSci and GTEx; Supplementary Table 5a). 
Ideally, the exact same ePair would have been tested across all tissues. However, due to 
differences in genotyping methods and allele-frequency due to sample size it was not always 
possible to query the exact same ePair in all tissues. To account for this, if the original lead 
variant was not available to test in the query tissue, a proxy variant was tested instead. We 
note that the selected proxy may differ across the replication tissues. The approach to define 
the proxy variant is summarized in the Supplementary Information.
Replication was defined as the query variant (original lead or proxy) having a nominal eQTL 
P < 2.2x10-04 for the same eGene (corresponding to P = 0.01 / 45, where 45 refers to the 
total number of tissues tested). A lenient threshold was chosen in order to rule out any 
evidence of replication. High-LD proxies for a lead were defined as having r2 > 0.8 in the 
UK10K European reference panel and located in the same cis window. All available LD-
proxies were tested for replication and the variant with the most significant eQTL P-value in 
the discovery tissue was stored as the proxy. If no LD-proxies could be tested, the cis variant 
with the most significant eQTL P-value in the discovery tissue overall was selected. Overall, 
the same lead variant was available to test in 95% of tests across tissues (median of 
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discovery tissues, with each discovery tissue represented as the median of tests across all 
replication tissues; 90% for iPSC eQTLs). A high-LD proxy for the lead was tested 3.6% of 
the time (7.3% in iPSC), while the best available cis variant was tested only 1.1% of the time 
(2.7% in iPSC). Of the rare cases when the best available variant was tested, the selected 
variant was independent of the original eQTL effects (r2 < 0.1) 0.2% of the time (1.2% in 
iPSC), indicating that in the vast majority of cases, the same eQTL effect was tested for 
replication and the choice of variant is unlikely to have a marked effect on the results. 
Statistics of the replication of the iPSC eQTLs, including numbers of selected proxy 
variants, are provided in Supplementary Table 5b. If a gene was not tested for eQTLs in the 
query tissue (for e.g. due to gene not expressed), replication information was defined as 
missing. A replication profile was derived for each eGene in the discovery tissue, indicating 
whether the lead eQTL effect replicated (yes | no) or could not be tested (‘NA’). We then 
extracted eGenes, for which the lead eQTL effect did not show evidence of replication in 
any other tissue (P > 2.2x10-04) or could not be tested (hereon referred to as ’tissue-specific 
eQTLs’). Of note, in this analysis, for an eQTL effect to replicate, it has to affect the 
expression of the same gene in both tissues. It the same variant is an eQTL for two different 
genes in the two tissues, it is not considered replicating. We also investigated the impact of 
the specific replication threshold, considering a threshold of P<0.01 and P<0.05 (Extended 
Data Fig. 8c). This analysis showed that the ability to replicate an eQTL signal in a second 
tissue is primarily determined by the sample size of the replication tissue and not the specific 
choice of threshold. This dependency needs to be taken into account when interpreting 
tissue-specific eQTL effects.
As an alternative strategy for comparing eQTLs among different tissues, we also calculated 
the π1 statistic (π1 = 1 - π0; 75) for all pairs of tissues (Extended Data Fig. 8b) using the 
qvalue package in R. The π1 statistic provides a global measure of similarity between a pair 
of tissues by estimating the proportion of eQTL signal discovered in one tissue that shows 
evidence of replication in a second tissue. For this analysis, for each discovery tissue, we 
queried all significant variants per eGene in the full cis output of all other tissues and 
estimated q0 with the ‘bootstrap’ method of the qvalue package.
Functional annotation of eQTLs
Matched sets of variants: For all functional enrichment analyses, 100 matched sets of 
variants (hereon ‘control variants’) were used as the null. These sets were generated with 
SNPsnap 76 using unique lead eQTL variants from different datasets as the input. Variants 
were matched for minor allele frequency, number of SNPs in LD (‘LD buddies’; r2 > 0.5), 
distance to the nearest gene, and gene density, allowing for maximum deviation of +/- 50% 
for each criterion. HLA SNPs (defined as falling between positions 25,000,000 and 
35,000,000 on chromosome 6) were excluded from the analysis and all matched sets were 
non-overlapping with the input variants. 1000 Genomes Phase 3 European population was 
used as the genotype reference panel. Both target and control sets of variants were further 
expanded with their high-LD proxies (r2 > 0.8) derived from the European UK10k reference 
panel. These expanded sets form the basis for all subsequent enrichment analyses.
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Overlap with chromatin state annotations: Functional enrichment of eQTLs was assessed 
using chromatin state data from the Roadmap Epigenomics Project 27. The data comprised 
of 25 chromatin states derived from reference epigenomes from 127 cell types. We 
overlapped target eQTL variants separately with each chromatin state and cell type. We also 
overlapped 100 sets of control variants with the same annotations and derived an empirical 
P-value for each enrichment. This was defined as the number of control variant sets (N) that 
showed a higher overlap with the target annotation than the eQTL lead variants (P = N/100). 
The empirical P-values were further adjusted for the number of tests (25 states x 127 cell 
types) within each eQTL set using the Q-value 75 package in R. Annotations with a Q-value 
< 0.05 were considered significantly enriched. We tested two sets of eQTLs for enrichment: 
iPSC-specific eQTLs (N = 2,131) and non-specific eQTLs (N = 4,500).
For visualization purposes we aggregated the 127 cell types into five clusters, using k-means 
clustering. The number of clusters was chosen based on the number of different sample 
types annotated by Roadmap (primary cell, primary culture, primary tissue, cell line, ESC 
derived). A heatmap of the difference in fold enrichment between iPSC-specific and non-
specific eQTLs (DIFF = FEspecific - FEnonspecific) was generated with the pheatmap package 
in R (Fig. 4d) in order to assess how well our definition of iPSC-specific enriches for 
functional elements active in stem cells.
Overlap with transcription factor binding sites: Functional enrichment of eQTLs was 
additionally assessed using ChIP-seq based transcription factor (TF) binding sites (TFBS) 
from the ENCODE Project 49. Specifically, we used a set of proximal and distal TFBSs, 
where proximal is defined as a 2,000 bp window centered on Gencode v19 annotated 
transcription start sites (TSS). These sets were constructed by overlaying TF ChIP-seq peaks 
from all available cell types with DNase peaks. We limited our analysis to those peaks that 
overlapped with H1-ESC derived TF peaks. As with chromatin state annotations, we 
overlapped target and control eQTL variants with binding sites for each individual factor (all 
sites where the given factor is bound or co-bound). An empirical P-value for the enrichment 
was derived based on the control sets and adjusted for multiple testing using the Benjamini-
Hochberg method. Factors with an adjusted P < 0.05 were considered enriched. Plotted in 
Fig. 4 are factors with at least 10 observed overlaps.
Overlap with the GWAS catalogue: The NHGRI-EBI GWAS catalogue was downloaded 
on 2016-04-18 (release 2016-04-10). Entries with missing positional or P-value information 
were removed and the positions of the remaining entries were converted to hg19 with the 
UCSC liftOver function in the “rtracklayer” R/Bioconductor package 77 and the 
‘hg38ToHg19’ chain file. This resulted in 24,861 catalogue entries, corresponding to 18,446 
unique variants of which 6,681 were significantly associated to a trait (P < 5x10-08). 
However, many studies included in the complete catalogue are not reliable, so we parsed the 
sample size information in the catalogue and excluded studies that did not report effect sizes 
(odds ratio or regression coefficient), had a sample size below 1,000, or assayed fewer than 
100,000 variants. Then, following the approach taken in 78, we further filtered the set of 
remaining associations to retain only traits that had at least six significantly associated 
variants, and kept all associations with P < 1x10-06 for these traits. This approach yielded a 
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filtered set of 9,562 associations for 6,059 variants with 358 diseases and traits. Each variant 
position was then parsed for trait overlap (all traits associated to the given variant). If a 
variant - trait association was reported multiple times (e.g. by different studies), the most 
significant association was kept.
We first tested whether eQTLs in iPSCs and somatic tissues (lead variants and their high-LD 
proxies, control variants as before) showed global enrichment in this final set of disease-
associated variants compared with matched sets of variants (Extended Data Fig. 9b). Fold 
enrichments were derived from a comparison to 100 sets of matched controls (mean of 
control overlaps per tissue). For iPSCs, we additionally tested enrichment for individual 
traits, deriving an empirical P-value. Traits with an adjusted P < 0.05 (Benjamini-Hochberg) 
and minimum five observed overlaps were considered enriched (Supplementary Table 6c).
Lastly, we parsed each disease variant position for overlap with iPSC eQTLs, again 
considering lead variants and their high-LD proxies for each tissue as follows. We report all 
disease variants that were tagged by iPSC eQTLs (lead or proxy) and the eGene(s) regulated 
by the eQTL lead/proxy (Supplementary Table 6a). We additionally report a subset of these 
variants that are exact matches with iPSC lead eQTL variants and highlight the number of 
high-LD proxies (r2 > 0.8) each variant has (Supplementary Table 6b).
Colocalisation analysis: We used coloc v2.3-1 29 to test for colocalisation between 
molecular QTLs and GWAS hits from Alzheimer’s disease 79, celiac disease 80, 
inflammatory bowel disease, ulcerative colitis, and Crohn’s disease 81, multiple sclerosis 82, 
83, narcolepsy 83, primary biliary cirrhosis 84, psoriasis 85, rheumatoid arthritis 86, 
schizophrenia 87, systemic lupus erythematosus 88, type 1 diabetes 89 and type 2 diabetes 
90. We ran coloc on a 250 Kb region centered on the eQTL gene for all eQTL variants that 
were less than 100 Kb away from at least one GWAS variant with nominal P < 1x 10-5. We 
then applied a set of filtering steps to identify a stringent set of eQTLs that colocalised with 
GWAS hits. We removed all cases with <50 SNPs in the cis region and selected only loci 
where PP3 + PP4> 0.5 and PP4/(PP3+PP4) > 0.5 to only keep loci where coloc strongly 
preferred a model of QTL for both traits, of a single shared causal variant driving both 
association signals over a model of two distinct causal variants. We excluded all 
colocalisation results from the MHC region (GRCh37: 6:28477897-33448354) because 
these could exhibit an elevated false positives rate due to the complicated LD patterns in this 
region. We kept only results where the minimal GWAS P-value was < 5x10-8.
Overlap with the COSMIC genes: To assess the overlap of iPSC eQTLs with known 
cancer genes in the context of somatic and cancerous tissues, we calculated the cumulative 
number of cancer genes (COSMIC cancer census 27/04/2016; Ngenes = 571 20) regulated by 
eQTLs in iPSCs, somatic tissues (GTEx V6p), and three different cancers (ER positive and 
negative breast cancer, colorectal cancer) 36,37 (Extended Data Fig. 9a).
Splicing of TERT: Alternative splicing of the TERT gene was analysed using Leafcutter 91, 
which focuses on introns and quantifies both known and novel alternative splicing events by 
quantifying reads mapping to exon-exon junctions. Annotations were derived from Gencode 
v19. Introns supported by fewer than 30 reads (-m 30; default) across all samples were 
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removed. We obtained quantifications for eight intron clusters within TERT. After removing 
individual introns with a mean intron usage of zero, we had a total of 22 introns to test. We 
used the intron excision proportions to assess genotype-dependent effect of rs10069690 on 
TERT splicing (linear model between genotype and excision proportion, Bonferroni 
correction of P-values for the total number of introns tested). One intron showed evidence of 
a splicing-QTL effect (P < 0.05, Bonferroni adjusted; Extended Data Fig. 10).
Data availability
The assay data used in this publication are listed in the Biostudies archive (https://
www.ebi.ac.uk/biostudies/studies) with accession identifier S-BSMS5. All data can be 
accessed via the HipSci data portal (http://www.hipsci.org), which references to EMBL-EBI 
archives that are used to store the HipSci data. Managed access data from all assays are 
accessible via EGA under the study EGAS00001001465. Open access genotyping array data 
and RNA-seq data are available from ENA under the studies PRJEB11752 and PRJEB7388. 
Open access gene expression array data are available in the ArrayExpress database under 
accession number E-MTAB-4057. The mass spectrometry proteomics data have been 
deposited to ProteomeXchange via the PRIDE repository with the dataset identifiers 
PXD003903 and PXD005506. Data types from specialized assays for which none of the 
existing archives are appropriate are available from the HipSci FTP site (ftp://
ftp.hipsci.ebi.ac.uk/vol1/ftp). Intermediate result files for this study, such as processed gene 
expression levels, can be found at: ftp://ftp.hipsci.ebi.ac.uk/vol1/ftp/data. For full details see 
Supplementary Information.
Code availability
Scripts that were used to process the raw data and for implementing the statistical analyses 
presented are available from https://github.com/hipsci/Nature2017.
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Extended Data
Extended Data Figure 1. Overview of the Cellomics assay.
(a) Example plate layout for the cellular differentiation assay. Images are shown for the 
pluripotency markers (Oct4, Sox2, and Nanog) as they are measured in the Cellomics 
imaging device. Each line is measured in two rows of the same plate as technical replicates. 
The secondary antibody used for each marker is shown in parenthesis. Each plate also has 
measurements for staining with the secondary antibody only, which serves as a means to 
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assess background fluorescence. The red channel shows the signal from the DAPI staining, 
the green channel the marker signal. As expected, there is only little signal from the green 
channel in the wells stained only for the secondary antibody. Image acquisition stops as soon 
as 10,000 cells have been detected. (b) Detailed variance components of the Cellomics 
markers (Methods). Substantial proportions of the marker variance could be attributed to 
batch factors, including staining, technician effects and antibody lots. These effects mean 
that the fraction of cells expressing particular markers need to be interpreted with caution 
(Fig. 1c,d). (c) Pairwise correlation between quantitative expression scores derived from 
immunostaining for pluripotency and differentiation and the PluriTest score.
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Extended Data Figure 2. Pluritest scores in the two culture conditions
(a-c) Comparison of PluriTest novelty score versus pluripotency score for the 711 lines 
generated. Lines grown on feeder-free conditions (E8 media) scored systematically lower 
than Feeder-dependent lines (P = 1.62x10-43 t-test, for pluripotency score). We note that, 
while we cannot rule out that Feeder-free lines are less pluripotent, Feeder-free conditions 
are not well represented in the PluriTest training dataset, which may explain this result (of 
the 204 ESC/IPSC lines in the pluriTest paper that have media metadata available, none 
were on E8 and only 37 were on a variety of other feeder free formulations such as 
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MTSER). (d) Despite lower pluripotency scores, lines grown on Feeder-free conditions have 
higher fractions of cells expressing canonical protein markers of pluripotency.
Extended Data Figure 3. Extended CNA analysis.
Relationship between the number of CNAs using three CNA minimum length thresholds for 
calling CNAs: 200 Kb, 500 Kb and 1,000 Kb and other experimental factors. Values on the 
x-axis have been ‘jittered’ (i.e. small random ‘noise’ has been added to the true values) to 
enhance the visualisation. Data points underlying the boxplots are shown as semi-transparent 
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blue dots. (a) Number of CNAs per line versus passage number. P-values shown are from a 
generalized linear mixed model (Poisson regression) with donor random effect. (b) Boxplot 
of the number of autosomal CNAs per line versus growth media. P-values are for a Poisson 
regression on culture condition. (c-d) Number of autosomal CNAs per line versus PluriTest 
pluripotency and novelty scores. P-values are for a linear mixed model on the number of 
autosomal CNAs per line with a donor random effect. (e-f) Number of CNA counts per 
donor versus gender and donor age. CNA counts refer to the total number of unique CNAs 
across all lines derived from the same donor. CNAs that are shared between lines of the 
same donor (overlap by at least one base) are counted only once. P-values shown are for a 
Poisson regression on either gender or age.
Extended Data Figure 4. Location and consequence of the recurrent CNA on chr20 (related to 
Fig. 2).
Top panel shows genomic location versus number of lines with CN three (grey) and with a 
CNA (black). Bottom panel shows the NAV gene score from ref22 and log2 gene expression 
fold change between the iPSC lines with CN two and three (color scale), in the region 
highlighted in red in the top panel. Highlighted genes are up-regulated when copy number 
increases, known onco/tumour-suppressor genes and/or genes with NAV score in the top 2%.
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Extended Data Figure 5. Functional assessment of CNAs using growth assays.
Cell growth rate (a), proliferation (b) and apoptosis (c) in cell lines with copy number two 
(“wild type”, blue dots) or copy number three (“mutant”, red dots) in a recurrently 
duplicated region in iPSCs on chromosome 1, 17 or 20. Plot titles show the donor name and 
the genomic coordinates of the CNA. (a) Shown are cell counts taken on successive days in 
culture, for pairs of lines (one mutant, one wild type) grown on the same 24-well plates. Star 
symbols denote significance levels for statistical interactions between day and copy number 
in a linear mixed model, using fixed effects to fit day and copy number, and random effects 
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to account for culture plate effects. “EIF4A3” denotes whether a copy number variant 
overlaps one of the suspected candidate genes on chromosome 17. * - P < 0.05; ** - P < 
0.01; *** - P < 0.001. (b) Protein expression level measured using Tandem Mass Tag 
(TMT)-based quantitation on the Q-exactive plus (labelled “QE Plus”) orbitrap and a fusion 
(labelled “Fusion”) orbitrap MS platforms. (c) Estimated fraction of fluorescing nuclei 
following EdU assay in mutant and wild type lines, following exposure to mitomycin 
("Treated"), or in a control sample ("Untreated"). (d) Estimated fraction of fluorescing 
nuclei following Terminal deoxynucleotidyl transferase dUTP nick end labelling assay 
(TUNEL) in mutant and wild type lines, following exposure to mitomycin ("Treated"), or in 
a control sample ("Untreated"). Solid trend lines are least squares regression fits. P-values in 
b and c denote the significance of statistical interactions between copy number and 
mitomycin treatment condition (“Treated” or “Untreated”).
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Extended Data Figure 6. Effect of passage on Tier 1 and Tier 2 data and overview of iPSC cis 
eQTLs mapped with ‘Tier 1’ gene expression array data.
(a,b) Passage number versus PluriTest pluripotency and novelty scores shows no significant 
association between passage number and pluripotency. Trend lines shown are fit using linear 
regression of PluriTest scores on passage number (score P = 0.66, novelty P = 0.21). 
Association was also not deemed significant when including gender and media as fixed 
effects and batch variables and donor as random effects (score P = 0.3, novelty P = 0.14). (c) 
Passage number versus log10 RNA-seq expression of pluripotency factors Nanog and 
Pou5f1 (Oct4) shows no significant association between passage number and pluripotency. 
Trend lines are fit using linear regression of log10 expression on passage number (Nanog P 
= 0.5, Pou5f1 P = 0.15). Association was also not deemed significant when considering the 
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two genes together and when including gender and media as fixed effects and batch 
variables and donor as random effects (passage P = 0.28, passage-gene interaction P = 0.96). 
(d,e) Variance component analysis for Tier 2 assays, showing that for the majority of genes 
gender and passage explained little of the total variance. (f,g) Comparison of eQTL effect 
sizes (squared beta) at lead variants of the main gexarray eQTL map (derived using mean 
expression levels per donor). Plotted are the effect sizes for all tested genes (FDR < 5% 
eGenes indicated in blue) derived from (f) iPSC line replicate sets 1 and 2, one per donor, 
drawn randomly (rho = 0.47 genome-wide, rho = 0.80, FDR < 5% eGenes, P < 2.2e-16; 
Spearman rank correlation) and (g) replicate set 1 and the main map (rho = 0.57 genome-
wide, rho = 0.88, FDR < 5% eGenes, P < 2.2e-16). Panel (g) shows that the effect sizes 
obtained using the mean expression values per donor are higher than when using individual 
lines. (h) Pairwise correlation between gene expression levels in iPSCs measured with RNA-
seq and gexarray. Plotted are the Spearman rank correlation coefficients of either gene (pink) 
or gexarray probe (blue) region based read counts, demonstrating higher correlation of 
probe-based counts.
Extended Data Figure 7. Properties of iPSC cis eQTLs in comparison to somatic eQTLs.
Plotted is the power to detect eQTLs, comparing 44 somatic tissues from GTEx 24 (V6p) 
and the HipSci RNA-seq -based eQTL map (purple triangle), considering either the absolute 
(a) or relative (b) number of eQTLs identified (eGenes, FDR < 5%). The major determinant 
of eQTL detection power is sample size. (c) Cumulative fraction of RNA-seq reads relative 
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to the number of protein coding genes expressed. Plotted is the mean read count derived 
from 20 iPSC lines (10 donors, two lines each), five fibroblast lines, and two embryonic 
stem cell (ESC) lines. In iPSCs, half of the reads are explained by the expression of 1,071 
genes, while 75% and 90% of the reads are explained by the expression of 3,159 and 5,814 
genes, respectively (total protein coding genes with non-zero counts N = 17,332). (d) 
Distribution of iPSC eQTLs around the annotated gene start position. Plotted is the -log10 
(eQTL P-value) against the distance (bp) from the gene start for lead eQTL variants 
genome-wide, highlighting significant eQTLs (FDR < 5%) in orange. (e) Comparison of the 
magnitude of eQTL effect size (absolute beta; left panel) and minor allele frequency (MAF; 
right panel) between iPSC-specific (N = 2,131; labelled as ‘S’) and non-specific eQTLs (N = 
4,500; labelled as ‘NS’), demonstrating that overall, iPSC-specific eQTLs have smaller 
effects on the transcriptome than eQTLs shared among multiple tissues (P = 9.97x10-161; 
Wilcox test) and have a lower minor allele frequency (P = 1.08x10-35, Wilcox test).
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Extended Data Figure 8. Comparison of eQTL mapping pipelines between HipSci and GTEx 
(V6p).
(a) Proportion of tissue-specific eQTLs as a function of the discovery sample size. For iPSC, 
shown are the two sets of tissue-specific eQTLs obtained with the two different mapping 
pipelines (Methods), namely the standard HipSci pipeline (‘iPSC’; purple triangle) and the 
alternative ‘GTEx-like’ pipeline (‘iPSC2’; purple triangle). Points other than iPSC are from 
the GTEx Consortium (44 somatic tissues and cell lines) 24. (b) Heatmap of pairwise π1 
values (π1 = 1 - π0) between iPSCs and GTEx tissues, with rows representing the discovery 
tissue and columns the replication tissue. Clustering of tissues is based on euclidean distance 
(R hclust, method=average). (c) Effect of eQTL replication threshold on the definition of 
tissue-specific effects. Shown is the replication profile of iPSC eQTLs across GTEx tissues 
relative to discovery sample size in each replication tissue. Plotted is the proportion of iPSC 
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lead eQTLs that replicate in each tissue, with replication defined using two different 
replication thresholds (TH1: nominal eQTL P < 0.01/N_tissues; TH5: P < 0.05/N_tissues; 
plotted as dots and triangles, respectively). (d) Enrichment of alternative iPSC eQTLs 
(‘GTEx-like”) at promoter proximal and distal (defined as less than or greater than 2 Kb 
from the transcription start site) transcription factor binding sites (TFBS) in H1-hES cells 
from the ENCODE Project 49. Fold enrichments per factor are shown for iPSC-specific and 
non-specific eQTLs (minimum 10 observed overlaps) (Methods). Pluripotency-associated 
factors are indicated with an asterisk. The profile of enrichments is comparable to that 
obtained with the standard HipSci pipeline (Fig. 4d).
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Extended Data Figure 9. iPSC eQTLs and disease.
(a) Cumulative number of cancer genes (COSMIC cancer census 27/04/2016; Ngenes = 571 
20) regulated by eQTLs in iPSCs, somatic tissues (GTEx V6p), and three different cancers 
(ER positive and negative breast cancer, colorectal cancer) 33,34. (b) Enrichment of iPSC 
and somatic eQTLs (lead variants and their high-LD proxies) at disease-associated variants 
in the NHGRI-EBI GWAS catalogue (2016-04-10). Plotted is the fold enrichment of eQTLs 
over 100 random sets of matched variants for each tissue relative to eQTL discovery sample 
size. The tissues showing the highest fold enrichment are liver and brain (cerebellar 
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hemisphere; ‘BrainCH’’). (c) Somatic eQTL signal for PTPN2 (Protein Tyrosine 
Phosphatase, Non-Receptor Type 2) locus on chromosome 18. This locus contains a 
colocalising association signal for PTPN2 gene expression in iPSCs and five immunological 
disease phenotypes (Fig. 5a). (d) Somatic eQTL signal for TERT (Telomerase Reverse 
Transcriptase) locus on chromosome 5 (Fig. 5b). In both (c) and (d), the lead eQTL variant 
locations are indicated with red and orange vertical lines for iPSC and somatic tissues, 
respectively. The focal gene regions are indicated in solid grey and gene start positions of 
other protein-coding genes on the same strand with vertical grey lines.
Extended Data Figure 10. Tissue expression and alternative splicing results at the TERT locus.
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(a,b) Normalised RNA-seq per-base coverage across the TERT locus stratified by 
rs10069690 genotype. Plotted in the full locus (a), while (b) shows a zoomed view of the 
region around the lead eQTL and cancer risk variant rs10069690, indicated with a dotted 
line on each plot. Grey regions indicate annotated exons from Ensembl v75. Coverage was 
computed from indexed BAM files using the coverageBed function from the bedtools 
(v2.25.0) 92. Raw coverage was divided by total library size in millions (total number of 
mapped reads) per sample to obtain normalised coverage, which was then averaged over 
samples with the same rs10069690 genotype to obtain mean normalised coverage for each 
genotype group. (c) Profile of TERT expression in iPSCs and across somatic tissues from 
GTEx. Shown are gene FPKM values obtained with RNA-SeQC (GTEx V6p). (d) Splicing-
QTL of TERT. We quantified TERT intron retention rates using Leafcutter {Li, 2016 #443} 
and identified one alternative splicing event associated with rs10069690, the lead iPSC 
eQTL variant for TERT (Fig. 5b). Shown is TERT intron 4 retention ratio (PSI, percent 
spliced in) in iPSC lines of all individual donors stratified by their genotype at rs10069690. 
This variant affects the splicing of the intron where it is located, with the minor allele (T) 
increasing the fraction of TERT transcripts in which intron 4 is retained (P = 1.7x10-9, 
Bonferroni adjusted linear regression).
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Figure 1. iPSC line generation and quality control.
Throughout light blue = not selected, dark blue = selected lines. (a) hDF: human dermal 
fibroblasts; dEN: differentiated endoderm; dME: differentiated mesoderm; dEC: 
differentiated neuroectoderm. The x-axis shows the median number of days, including 
freeze/thaw cycles (snowflakes), at each pipeline stage, with stage-specific success rates. (b) 
PluriTest pluripotency versus novelty score9. (c,d) Percentage of cells expressing 
pluripotency and differentiation markers. (e) Cumulative distribution of number of CNAs, 
fraction of trisomies per chromosome (inset). (f) Relationship between CNA counts and line 
passage number.
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Figure 2. Locations and consequences of recurrent CNA regions.
(a) Genomic locations of CNAs. Colours denote the significance level of recurrence. (b) 
Genes differentially expressed between lines with CN 2 and 3 for the recurrent chr17 CNA. 
Horizontal bar denotes 1% FDR threshold (Benjamini-Hochberg). (c) Top panel shows 
genomic location versus number of lines with CN 3 (grey) and with a CNA (black). Bottom 
panel shows the NAV gene score from ref22 and log2 gene expression fold change between 
the iPSC lines with CN 2 and 3 (color scale), in the region highlighted in red in the top 
panel. Highlighted genes are up-regulated when copy number increases, known onco/
tumour-suppressor genes and/or genes with NAV score in the top 2%.
Kilpinen et al. Page 47
Nature. Author manuscript; available in PMC 2017 November 10.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 3. Variance component analysis of HipSci assays.
(a-c) Partitioning of variance in genomic and proteomic assays (a), differentiation and 
pluripotency markers (b) and cell morphology (c). Panels show total variance (left) and 
proportion of variance explained by donor, accounting for technical covariates (right), with 
numbers of lines and donors in parenthesis. For genomic assays, genes are divided into low 
(L), medium (M) and high (H) expression. (d) Partitioning of variance in microarray gene 
expression into donor, media, CNA, gender or passage number at the time of the expression 
assay. Left: the distribution of variance components. Middle: the number of genes where 
each factor explains the most variance. Right: mean expression of genes with most variance 
explained by a factor. (e) Donor variance component versus expression array eQTL effect 
sizes. Numbers denote the number of array probes in each bin.
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Figure 4. Comparison of iPSC and somatic tissue eQTLs.
(a) Proportion of tissue-specific eQTLs in iPSCs and 44 GTEX tissues24. (b) Most likely 
source of tissue-specific eQTLs in iPSCs (lead and secondary), testis and somatic tissues in 
GTEx (averaged; including cell lines, excluding testis). Breakdown: gene not expressed 
(red); gene expressed but no eQTL (blue); eQTL effect is driven by distinct lead variants (r2 
< 0.8; green). (c) Heatmap of the fold enrichment (FE) difference between iPSC-specific and 
non-specific eQTLs at chromatin states from the Roadmap Epigenomics Project27, shown 
for five aggregated clusters representing 127 cell types (SOM, somatic; PSCd, PSC-derived). 
Colouring: enriched for iPSC-specific eQTLs (blue), enriched for non-specific eQTLs (red). 
(d) Enrichment of iPSC eQTLs at promoter proximal and distal transcription factor binding 
sites in H1-hES cells from the ENCODE Project49. Fold enrichments per factor are shown 
for iPSC-specific and non-specific eQTLs. Pluripotency-associated factors are indicated 
with an asterisk.
Kilpinen et al. Page 49
Nature. Author manuscript; available in PMC 2017 November 10.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 5. iPSC eQTLs tag disease-associated variation.
(a) Colocalised association signal for iPSC expression of PTPN2 (top) and five common 
diseases (bottom; inflammatory bowel disease, IBD; rheumatoid arthritis, RA; Crohn’s 
disease, CD; celiac disease, CEL; and type 1 diabetes, T1D). PP4 is the posterior probability 
that the disease and gene expression associations are driven by the same causal variant29. 
(b) An iPSC-specific eQTL for TERT (rs10069690) that is associated with risk for breast, 
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ovarian and other cancers.33,34 The lead variant is indicated with a red triangle, the focal 
gene region in solid grey, and other protein-coding gene start positions by vertical grey lines.
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